

LncRNA *JHDM1D-AS1* Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells

Isadora Oliveira Ansaloni Pereira ^{1,†}, Glenda Nicioli da Silva ^{1,*,†}, Tamires Cunha Almeida ², Ana Paula Braga Lima ¹, André Luiz Ventura Sávio ^{3,4}, Katia Ramos Moreira Leite ⁵ and Daisy Maria Fávero Salvadori ⁶

¹ Departamento de Análises Clínicas, Pharmacy School, UFOP—Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil

² Laboratory of Pain and Signaling, Butantan Institute, Sao Paulo 05503-900, SP, Brazil

³ Departamento de Odontologia, Faculdade do Centro Oeste Paulista—FACOP, Piratininga 17490-000, SP, Brazil

⁴ Departamento de Ciências Médicas, Universidade do Oeste Paulista—UNOESTE, Jaú 19050-900, SP, Brazil

⁵ Departamento de Cirurgia, Medical School, USP—University of São Paulo, São Paulo 05508-060, SP, Brazil

⁶ Departamento de Patologia, Medical School, UNESP—São Paulo State University, Botucatu 01151-000, SP, Brazil

* Correspondence: nicioli@ufop.edu.br

† These authors contributed equally to this work.




Figure S1. Chromosome location, structural organization, and length of *JHDM1D* and *JHDM1D-AS1* genes.




Figure S2. Relative expression of *JHDM1D-AS1* in J82 and UM-UC-3 cells after 72h of siRNA-*JHDM1D-AS1*.




Figure S3. Percentage of J82 cells in each phase of cell cycle after treatment with gemcitabine, siRNA *JHDM1D-AS1*, or gemcitabine combined with siRNA *JHDM1D-AS1*. Control: untreated cells; gem: gemcitabine. a: $p < 0.05$ compared to control; b: $p < 0.05$ compared to siRNA; c: $p < 0.05$ compared to respective gemcitabine concentration alone.




Figure S4. Percentage of UM-UC-3 cells in each phase of cell cycle after treatment with gemcitabine, siRNA *JHDM1D-AS1*, or gemcitabine combined with siRNA *JHDM1D-AS1*. Control: untreated cells; gem: gemcitabine. a: $p < 0.05$ compared to control; b: $p < 0.05$ compared to siRNA; c: $p < 0.05$ compared to respective gemcitabine concentration alone.




Figure S5. Photographs of cell migration in J82 cells after treatment with gemcitabine. Control: untreated cells; Gem: gemcitabine.




Figure S6. Photographs of cell migration in J82 cells after treatment with gemcitabine. Control: untreated cells; Gem: gemcitabine.